Use of Pre-Emptive Pudendal Nerve Block for Pelvic Reconstructive Surgery

NCT ID: NCT02409498

Last Updated: 2017-04-25

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-10-31
• Study Completion Date: 2015-10-31

Brief Summary

The purpose of this study is to determine the effectiveness of perineal pain control via injection of a local anesthetic to numb the pudendal nerve. The medication which is commonly used for this block is called marcaine. This is called a pudendal block it has been used in obstetrical and gynecologic surgeries for several decades. The goal of this study is to reduce the amount of pain medications taken post operatively after pelvic reconstructive surgery. Subjects undergoing pelvic reconstructive surgery will be recruited during the pre-op visit. Subjects will be asked about their pain level in the PACU and also asked to document their pain score days 1 and 2 post op. They will also be asked to keep a medication log for 14 days post op.

Detailed Description

Subjects will have a through physical exam with evolution of the pelvis support using the POP-Q (pelvic organ prolapse quantification) system. All subjects will need to sign informed consent pre-approved by the IRB. The subjects, surgeons, and anesthesiologist will all be blinded to the injected material. The OR Scrub nurse will given the envelope at the start of each case and asked to draw the material into a syringe. All subjects will receive general anesthesia. Subjects will be randomized to receive preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine or normal saline to each side. The allocation schedule is computer generated using random-numbers table concealed in opaque envelops. Once the patient receives general anesthesia she will be positioned appropriately in dorsal lithotomy with padded Allan stir ups. 10 ml of Bupivacaine will be injected on either side using the Iowa trumpet pudendal needle drive to direct and guide appropriate position. Aspiration was attempted for every injection to decrease the chance of intravascular infusion.

At the completion of the surgery the subjects will be brought to the PACU for care. Patients are assessed immediately upon arrival to the PACU. The patients are asked their pain level using the VAS pain scale/ modified surgical pain scale at hours 1 and 2 post op. All patients are given a prescription for Vicoprofen 7.5/200mg at their pre-op visit and asked to have it filled prior to their surgery. Patients have the option to go home the same day of surgery as long as their pain is well controlled and they are clinically stable for discharge. Continued pain management and pain scale assessment will be done at 4 hours, and post op day 1 and 2. A medication log will be kept for 2 weeks post op, detailing the number of pain medications taken during that period.

Conditions

Pelvic Organ Prolapse

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: QUADRUPLE

Study Groups

pudendal block

preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine. 10 ml of Bupivacaine will be injected on either side using the pudendal nerve block tray.

Group Type: ACTIVE_COMPARATOR

pudendal block

Intervention Type: DRUG

preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine.

no pudendal block

Saline

Group Type: PLACEBO_COMPARATOR

no pudendal block

Intervention Type: DRUG

preemptive pudendal nerve blockade with 10 ml of normal saline to each side

Interventions

pudendal block

preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine.

Intervention Type: DRUG

no pudendal block

preemptive pudendal nerve blockade with 10 ml of normal saline to each side

Intervention Type: DRUG

Other Intervention Names

Bupivicaine; Marcaine; Saline; salt water; placebo

Eligibility Criteria

Inclusion Criteria

• The ability to read and understand English
• Be at least 18 years old
• Symptomatic Stage 2 prolapse

Exclusion Criteria

• Intolerance to local anesthetics or narcotics
• History of major psychiatric disorder or chronic pain syndrome
• History of substance abuse or current narcotic use

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Icahn School of Medicine at Mount Sinai

OTHER

Sponsor Role: lead

Responsible Party

Charles Ascher-Walsh

Director

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Mamta Mamik, MD

Role: PRINCIPAL_INVESTIGATOR

Icahn School of Medicine at Mount Sinai

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Countries

United States

References

Katz J, Kavanagh BP, Sandler AN, Nierenberg H, Boylan JF, Friedlander M, Shaw BF. Preemptive analgesia. Clinical evidence of neuroplasticity contributing to postoperative pain. Anesthesiology. 1992 Sep;77(3):439-46. doi: 10.1097/00000542-199209000-00006.

Reference Type: BACKGROUND

PMID: 1519781 (View on PubMed)

Ke RW, Portera SG, Bagous W, Lincoln SR. A randomized, double-blinded trial of preemptive analgesia in laparoscopy. Obstet Gynecol. 1998 Dec;92(6):972-5. doi: 10.1016/s0029-7844(98)00303-2.

Reference Type: BACKGROUND

PMID: 9840560 (View on PubMed)

Schierup L, Schmidt JF, Torp Jensen A, Rye BA. Pudendal block in vaginal deliveries. Mepivacaine with and without epinephrine. Acta Obstet Gynecol Scand. 1988;67(3):195-7. doi: 10.3109/00016348809004200.

Reference Type: BACKGROUND

PMID: 3051873 (View on PubMed)

Other Identifiers

GCO 13-1190

Identifier Type: -

Identifier Source: org_study_id